Sign in
Taking people in South KoreaNo phase

Predicting How Ulcerative Colitis Patients Respond to Treatments

Develops a model predicting response to vedolizumab, ustekinumab or tofacitinib in ulcerative colitis.

Key facts

Who runs it
Asan Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Status
Recruiting
People taking part
300 people, planned
Started
5 Feb 2022
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Vedolizumab, Ustekinumab, or Tofacitinib
Record updated
15 February 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Korean adults with ulcerative colitis who are going to start vedolizumab, ustekinumab, or tofacitinib. It will build a model to predict who responds to these drugs.

Age
18 to 79 years
Sex
All sexes can join.
Disease stage
Ulcerative colitis confirmed by symptoms, endoscopy and tissue (biopsy) findings.
Earlier treatment
The person is going to receive vedolizumab, ustekinumab, or tofacitinib. Having had the colon removed because of ulcerative colitis rules a person out.

Main reasons for not taking part

  • Not Korean ethnicity by family history
  • Inflammatory bowel disease that cannot be classified
  • Colon removed (colectomy) because of ulcerative colitis

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
  • Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment

Who cannot take part

  • Patients who already received colectomy due to ulcerative colitis
  • Inflammatory Bowel Disease Unclassified
  • Not Korean ethnicity by family history

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in South Korea

  • Asan Medical CenterSeoul, South KoreaContact: Byong Duk Ye, MD, PhDTaking people

About the trial

What the trial wants to find out

This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.

The group in the trial

  • Patients with confirmed ulcerative colitis

    Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.

    Treatment: Vedolizumab, Ustekinumab, or Tofacitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerative Colitis Using Longitudinal Data
Plain-language title
Predicting How Ulcerative Colitis Patients Respond to TreatmentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05186623, who can take part
Record updated
15 February 2022